Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities.
Cardiovascular disease is the leading cause of death in patients with diabetes mellitus and represents a persistent risk that is inextricably linked to the diabetic disease state. The growing number of United States Food and Drug Administration-approved antidiabetic agents provides a wide range of therapeutic options, both as monotherapy and combination therapy, for treating hyperglycemia in patients with type 2 diabetes. Long-term clinical experience with many of these agents has revealed nonglycemic effects on lipid levels, inflammation, and cardiovascular function. Although some of these agents can improve cardiovascular disease risk in patients with diabetes, others may increase the risk and may be prohibited from use in certain populations. Thus, the effect of antidiabetic agents on cardiovascular health and safety must be considered when selecting the most appropriate therapy. A review of the current literature was undertaken to examine the effects of antidiabetic agents on cardiovascular disease, and with the help of illustrative patient case examples, useful information is provided for clinicians to individualize therapy for patients with type 2 diabetes.
Malesker
Mark A
MA
Department of Pharmacy Practice, Creighton University Medical Center, Omaha, NE 68178, USA. malesker@creighton.edu
D000284:Administration, Oral; D000368:Aged; D001549:Benzamides / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000517:prevention & control; D015897:Comorbidity; D000075202:Contraindications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology*; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D013453:Sulfonylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use
D001549:Benzamides; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones; C030516:meglitinide; D008687:Metformin